argenx
Manufacturing · Netherlands · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Laarderhoogtweg 25, Amsterdam, North Hol...Phone Number
+31107038441Website
www.argenx.comRevenue
$4.7 BillionStock Symbol
ARGXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About argenx
Argenx SE is a global immunology biopharmaceutical company developing antibody-based therapies for severe autoimmune diseases. Its lead product, VYVGART (efgartigimod), an FcRn blocker, is approved in 30+ countries for generalized myasthenia gravis, CIDP, and ITP, generating $4.2B in 2025 sales. The pipeline includes empasiprubart (complement inhibitor) and adimanebart (MuSK agonist), advancing toward "Vision 2030": 50,000 patients treated, 10 labeled indications.Explore more
argenx Org Chart
JB
Medical Affairs & Evidence Generation Head (U...
KB
Senior Director & Head of Global Patient Safe...
SL
Neuromuscular Medical Affairs Head (US)
BH
Director & Head of Medical Affairs Scientific...
LM
Coe Head of Patient Experience
KU
Global of Medical Writing Head
CB
Head of Field Clinical Educator, US
DG
Executive Director, Neuromuscular
TP
Senior Director, Payer and HEOR MSLs and Immu...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is argenx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once argenx has new funding data
Earning: See what the market has to say on argenx recently announced quarterly report
Click to see if argenx had a recent Job posting/layoffs
Check if argenx has recently received funding, and reach out quickly before it becomes old news!
argenx, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when argenx launches new products
Congratulate Masked Content for being promoted to Masked Content at argenx
Check out if argenx is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at argenx
Find more new buyers
Company Profile Activity
Activity Insights
argenx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
argenx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about argenx.
argenx financials insights
Gather financial insights about argenx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$54.4M
2017
Stock Offering
$100M
2020
Stock Offering
$750M
argenx Tech Stack
A closer look at the technologies used by argenx
See more technologies
Most Recent Scoops
Open Position
Person-Based
Medical Research, Pharmaceuticals
Project
argenx has announced that the ALKIVIA phase III study met its primary endpoint of mean total improvement score (TIS) at week 52 in a combined IMNM and DM population, with a p-value of 0.0011, demonstrating a clear and sustained separation between the active treatment and placebo arms over the full 52-week period.
Medical Research, Pharmaceuticals, Clinical Operations
Project
argenx has announced that in the pre-specified IMNM subtype analysis of the ALKIVIA trial, efgartigimod met the primary endpoint with a p-value of 0.0048, achieving a mean TIS of 45.05 in the active treatment arm versus 30.24 in the placebo arm, representing a treatment difference of 14.81 points at week 52 and marking the first phase III dataset ever generated in IMNM.
Medical Research, Pharmaceuticals
Open Position
argenx News & Media
argenx to Present at Upcoming Investor Conferences
September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September:UBS Just Upgraded Argenx Stock. Here's Why.
Argenx shares rally as UBS issues a bullish note. Here’s how high its analyst expects ARGX stock to fly in 2026.Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story
This biotech leader continues to rack up clinical successes.Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding argenx
Sign Up For FreeTo access detailed company insights
Argenx SE is a global immunology biopharmaceutical company developing antibody-based therapies for severe autoimmune diseases. Its lead product, VYVGART (efgartigimod), an FcRn blocker, is approved in 30+ countries for generalized myasthenia gravis, CIDP, and ITP, generating $4.2B in 2025 sales. The pipeline includes empasiprubart (complement inhib... Read More
